SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2131872

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2131872

Sepsis Diagnostics Market by Technology, Product, Sample, Test Type, Pathogen, End User - Global Forecast to 2031

PUBLISHED:
PAGES: 521 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The sepsis diagnostics market is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%. The global sepsis diagnostics market is expected to grow steadily over the forecast period, driven by the rising burden of sepsis and bloodstream infections, increasing ICU admissions, growing demand for rapid pathogen identification, and rising adoption of molecular diagnostics, automated microbiology platforms, immunoassays, and biomarker-based testing.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Technology, Method, Pathogen Type, Test Type, Sample Type, Plexity, Clinical Utility/Management Pathway, and End User
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

Market growth is further supported by the increasing focus on antimicrobial stewardship programs, the need to reduce diagnostic turnaround time, and the adoption of automated diagnostic workflows in hospital and reference laboratories. However, the high cost of advanced molecular diagnostic platforms, limited reimbursement for novel diagnostic technologies, the clinical complexity of sepsis presentation, workflow integration challenges, and a shortage of trained laboratory personnel are expected to restrain market growth to some extent.

Sepsis Diagnostics Market - IMG1

"Assays & reagent kits accounted for the largest share of the sepsis diagnostics market, by product, in 2025."

By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest market share, driven by their recurring use in blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Rising demand for pathogen detection kits, PCR-based reagents, syndromic testing panels, inflammatory biomarker assays, and sepsis-related consumables continues to support this segment's dominance. Additionally, the growing adoption of automated and molecular testing platforms across hospitals and reference laboratories is further strengthening demand for assays and reagent kits.

"Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025."

By technology, the global sepsis diagnostics market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry & blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard diagnostic approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. These technologies are widely used in hospital microbiology laboratories for pathogen detection, organism identification, and therapy guidance. However, molecular diagnostics is expected to grow faster over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for rapid pathogen and resistance marker detection.

"The Asia Pacific region is projected to grow at the highest CAGR in the sepsis diagnostics market from 2026 to 2031."

The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific region is projected to have the highest CAGR, driven by the rising burden of infectious diseases and bloodstream infections, expanding hospital and ICU infrastructure, rising healthcare expenditure, and growing adoption of automated microbiology and molecular diagnostic platforms. Growth is further supported by improving laboratory capacity, greater awareness of sepsis management, rising demand for rapid diagnostics, and large patient populations across China, Japan, India, South Korea, Australia, and Southeast Asia.

List of Companies Profiled in the Report

  • Biomerieux
  • Becton Dickinson and Company
  • Danaher Corporation
  • Diasorin S.P.A (Luminex)
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc
  • Bruker Corporation
  • Abbott Laboratories
  • Sysmex Corporation
  • Siemens Healthineers
  • Qiagen
  • Quidelortho Corporation
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Research Coverage

This research report categorizes the sepsis diagnostics market by product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region. The scope of the report covers detailed information on the major factors influencing the market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of key industry players, providing insights into their business overview, product portfolio, key strategies such as product launches, regulatory approvals, collaborations, partnerships, acquisitions, and expansions, as well as recent developments associated with the sepsis diagnostics market. This report also covers a competitive analysis of leading players and emerging companies in the sepsis diagnostics ecosystem.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall sepsis diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

  • Analysis of key drivers, including the high incidence of sepsis and bloodstream infections, growing adoption of rapid molecular and syndromic diagnostics, increasing focus on antimicrobial stewardship, and expansion of biomarker-based testing; restraints, including the high cost of advanced molecular diagnostic platforms and limited reimbursement for novel diagnostic technologies; opportunities, including AI-enabled sepsis diagnosis, clinical decision support, next-generation host-response biomarkers, rapid POC testing, and decentralized testing; and challenges, including clinical complexity, heterogeneous sepsis presentation, integration into hospital workflows, and a shortage of trained laboratory personnel
  • Product Development/Innovation: Detailed insights into newly launched and emerging sepsis diagnostics products, including automated blood culture systems, molecular diagnostic panels, syndromic testing platforms, immunoassays, biomarker-based tests, mass spectrometry-based microbial identification platforms, antimicrobial susceptibility testing solutions, and AI-enabled clinical decision support tools
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the sepsis diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with detailed assessment of major country-level opportunities and adoption trends
  • Market Diversification: Comprehensive information on product portfolios, technological developments, regulatory approvals, collaborations, partnerships, acquisitions, geographic expansions, and investments in the sepsis diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, technological capabilities, diagnostic platforms, service offerings, and competitive positioning of leading players, including bioMerieux SA, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Bruker Corporation, and DiaSorin S.p.A., among others

Show more
Product Code: MD 4575

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
  • 3.2 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
  • 3.3 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.4 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2026 VS. 2031
  • 3.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2026 VS. 2031
  • 3.6 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2026 VS. 2031
  • 3.7 SEPSIS DIAGNOSTICS MARKET, SAMPLE TYPE, 2026 VS. 2031
  • 3.8 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2026 VS. 2031
  • 3.9 SEPSIS DIAGNOSTICS MARKET, CLINICAL UTILITY/MANAGEMENT PATHWAY, 2026 VS. 2031
  • 3.10 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
  • 3.11 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 High incidence of sepsis and bloodstream infections
      • 4.2.1.2 Growing adoption of rapid molecular and syndromic diagnostics
      • 4.2.1.3 Increasing focus on antimicrobial stewardship and expansion of biomarker-based testing for early sepsis detection and risk assessment
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High cost of advanced molecular diagnostic platforms
      • 4.2.2.2 Limited reimbursement for novel sepsis diagnostic technologies
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 AI-enabled sepsis diagnosis and clinical decision support
      • 4.2.3.2 Development of next-generation host-response biomarkers
      • 4.2.3.3 Growth of rapid POC and decentralized testing
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Clinical complexity and heterogeneous presentation of sepsis
  • 4.3 UNMET NEEDS & WHITE SPACES
    • 4.3.1 UNMET NEEDS IN SEPSIS DIAGNOSTICS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL SEPSIS DIAGNOSTICS INDUSTRY
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • 5.5.1 SEPSIS DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 IMPACT OF US TARIFFS-SEPSIS DIAGNOSTICS MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON REGIONS
      • 5.11.4.1 North America
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Hospital and specialty clinics
      • 5.11.5.2 Pathology and reference laboratories
      • 5.11.5.3 Research laboratories, academic institutes, and CROs

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 HOST-RESPONSE DIAGNOSTICS (TRANSCRIPTOMICS & IMMUNE PROFILING)
    • 6.1.2 AI-ENABLED AND PREDICTIVE SEPSIS DIAGNOSTICS
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING (RAPID AST)
    • 6.2.2 NEXT-GENERATION SEQUENCING (NGS) AND METAGENOMIC SEQUENCING
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 CONTINUOUS PATIENT MONITORING & CLINICAL DECISION SUPPORT SYSTEMS (CDSS)
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF MAJOR PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON SEPSIS DIAGNOSTICS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES & MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY ANALYSIS
      • 7.1.1.1 North America
        • 7.1.1.1.1 US
        • 7.1.1.1.2 Canada
      • 7.1.1.2 Europe
        • 7.1.1.2.1 Germany
        • 7.1.1.2.2 UK
        • 7.1.1.2.3 France
        • 7.1.1.2.4 Italy
      • 7.1.1.3 Asia Pacific
        • 7.1.1.3.1 China
        • 7.1.1.3.2 Japan
        • 7.1.1.3.3 India
        • 7.1.1.3.4 Australia
      • 7.1.1.4 Latin America
        • 7.1.1.4.1 Brazil
        • 7.1.1.4.2 Mexico
      • 7.1.1.5 Middle East
        • 7.1.1.5.1 Africa
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
      • 7.2.1.1 Eco-friendly initiatives
    • 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
  • 8.6 REVENUE POTENTIAL
    • 8.6.1 COST DYNAMICS

9 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 BLOOD CULTURE MEDIA
    • 9.2.1 CONTINUED RELIANCE ON BLOOD CULTURE AS GOLD STANDARD FOR BLOODSTREAM INFECTION DIAGNOSIS SUSTAINS DEMAND
  • 9.3 ASSAYS & REAGENT KITS
    • 9.3.1 INCREASING ADOPTION OF RAPID MOLECULAR AND BIOMARKER-BASED TESTING DRIVES RECURRING DEMAND FOR ASSAYS AND REAGENT KITS
  • 9.4 INSTRUMENTS
    • 9.4.1 EXPANSION OF LAB AUTOMATION AND RAPID DIAGNOSTIC PLATFORMS ACCELERATES INVESTMENT IN ADVANCED INSTRUMENTS
  • 9.5 SOFTWARE
    • 9.5.1 IMPLEMENTATION OF LAB INFORMATICS AND ANTIMICROBIAL STEWARDSHIP SOLUTIONS SUPPORTS SOFTWARE ADOPTION

10 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
    • 10.2.1 AS REGULATORY AND CLINICAL GOLD STANDARD, BLOOD CULTURE HOLDS LARGEST MARKET SHARE
  • 10.3 IMMUNOASSAYS
    • 10.3.1 EXPANDING ADOPTION OF HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS ASSESSMENT AND ANTIMICROBIAL STEWARDSHIP DRIVES MARKET GROWTH
  • 10.4 MOLECULAR DIAGNOSTICS
    • 10.4.1 PCR
      • 10.4.1.1 Widespread hospital adoption of syndromic multiplex panels for rapid pathogen and resistance gene identification to propel market growth
    • 10.4.2 MICROARRAYS
      • 10.4.2.1 Stable utilization in established blood culture identification workflows supports moderate growth
    • 10.4.3 FISH/PNA-FISH
      • 10.4.3.1 Retention of rapid Gram stain-adjunct testing in cost-constrained laboratories sustains low-growth utilization amid progressive substitution
    • 10.4.4 DNA SEQUENCING & NGS
      • 10.4.4.1 Growing clinical interest in culture-independent broad-spectrum pathogen detection drives adoption, constrained by cost and reimbursement barriers
    • 10.4.5 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
  • 10.5 FLOW CYTOMETRY
    • 10.5.1 GROWING CLINICAL INTEREST IN CELLULAR HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS RISK ASSESSMENT SUPPORTS STEADY MARKET GROWTH
  • 10.6 MASS SPECTROMETRY
    • 10.6.1 RISING EMPHASIS ON RAPID DIAGNOSTICS, LAB AUTOMATION, AND ANTIMICROBIAL STEWARDSHIP PROPELS ADOPTION
  • 10.7 CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS
    • 10.7.1 WIDE UTILIZATION OF INFLAMMATORY BIOMARKERS AND RISING ADOPTION OF POC DIAGNOSTICS PROPEL MARKET GROWTH

11 SEPSIS DIAGNOSTICS MARKET, BY METHOD

  • 11.1 INTRODUCTION
  • 11.2 CONVENTIONAL DIAGNOSTICS
    • 11.2.1 RELIANCE ON MANUAL MICROBIOLOGICAL AND BIOCHEMICAL WORKFLOWS IN RESOURCE-CONSTRAINED AND LOW-THROUGHPUT SETTINGS SUSTAINS DEMAND
  • 11.3 AUTOMATED DIAGNOSTICS
    • 11.3.1 GROWING INSTALLATION OF AUTOMATED PLATFORMS TO EXPEDITE TIME-TO-RESULT AND ADDRESS STAFFING SHORTAGES DRIVES SEGMENT GROWTH

12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE

  • 12.1 INTRODUCTION
  • 12.2 BACTERIAL SEPSIS
    • 12.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
      • 12.2.1.1 Rising prevalence of carbapenem-resistant and ESBL-producing organisms driving demand for resistance-marker testing
    • 12.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
      • 12.2.2.1 Established diagnostic workflows for staphylococcal and enterococcal bloodstream infection sustain stable growth
  • 12.3 FUNGAL SEPSIS
    • 12.3.1 RISING INCIDENCE OF FUNGAL BLOODSTREAM INFECTIONS DRIVES DEMAND
  • 12.4 OTHER PATHOGEN TYPES

13 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE

  • 13.1 INTRODUCTION
  • 13.2 LABORATORY TESTS
    • 13.2.1 CENTRALIZATION OF BLOOD CULTURE, MOLECULAR, AND MASS SPECTROMETRY WORKFLOWS WITHIN ACCREDITED HOSPITAL LABORATORIES SUSTAINS THE DOMINANT SHARE
  • 13.3 POC TESTS
    • 13.3.1 EXPANDING NEAR-PATIENT LACTATE AND BIOMARKER TESTING TO MEET SEPSIS BUNDLE COMPLIANCE TIMELINES DRIVES GROWTH

14 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 14.1 INTRODUCTION
  • 14.2 WHOLE BLOOD
    • 14.2.1 EMERGENCE OF DIRECT-FROM-BLOOD MOLECULAR TESTING AND WIDESPREAD USAGE OF WHOLE BLOOD SPECIMENS DRIVE MARKET
  • 14.3 SERUM
    • 14.3.1 SUSTAINED RELIANCE ON SERUM AND PLASMA FOR BIOMARKER-BASED TRIAGE AND ANTIBIOTIC STEWARDSHIP MAINTAINS STABLE GROWTH

15 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY

  • 15.1 INTRODUCTION
  • 15.2 SINGLEPLEX
    • 15.2.1 RECURRING VOLUME OF SINGLE-ANALYTE BIOMARKER AND CHEMISTRY TESTING SUSTAINS MARKET SHARE
  • 15.3 MULTIPLEX
    • 15.3.1 WIDESPREAD ADOPTION OF SYNDROMIC PANELS DELIVERING SIMULTANEOUS PATHOGEN AND RESISTANCE GENE IDENTIFICATION DRIVES GROWTH

16 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY

  • 16.1 INTRODUCTION
  • 16.2 SEPSIS DIAGNOSIS
    • 16.2.1 EXPANDING AVAILABILITY OF ASSAYS AND WIDESPREAD TESTING TO DRIVE MARKET
  • 16.3 PATHOGEN IDENTIFICATION
    • 16.3.1 ENTRENCHED CULTURE AND IDENTIFICATION WORKFLOWS SUSTAIN SUBSTANTIAL VOLUME
  • 16.4 SEPSIS RISK STRATIFICATION
    • 16.4.1 RISING DEPLOYMENT OF AUTOMATED SEVERITY SCORING AND CELLULAR HOST-RESPONSE MARKERS INTEGRATED WITH EARLY WARNING SYSTEMS DRIVES HIGH GROWTH
  • 16.5 ANTIMICROBIAL STEWARDSHIP SUPPORT
    • 16.5.1 INSTITUTIONAL REQUIREMENT FOR STEWARDSHIP AND ESCALATING BURDEN OF ANTIMICROBIAL RESISTANCE TO DRIVE MARKET
  • 16.6 PROGNOSIS & OUTCOME PREDICTION
    • 16.6.1 LIMITED UTILITY OF PROGNOSTIC INFORMATION CONTINUES TO HINDER DEDICATED ADOPTION

17 SEPSIS DIAGNOSTICS MARKET, BY END USER

  • 17.1 INTRODUCTION
  • 17.2 HOSPITALS & SPECIALTY CLINICS
    • 17.2.1 INCREASING BURDEN OF SEPSIS AND GROWING ADOPTION OF RAPID DIAGNOSTIC WORKFLOWS IN ACUTE CARE SETTINGS TO DRIVE MARKET LEADERSHIP
  • 17.3 PATHOLOGY & REFERENCE LABORATORIES
    • 17.3.1 INCREASING OUTSOURCING OF SPECIALIZED MICROBIOLOGY AND MOLECULAR TESTING SUPPORTS STEADY MARKET GROWTH
  • 17.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
    • 17.4.1 EXPANDING SEPSIS BIOMARKER RESEARCH AND DIAGNOSTIC INNOVATION CONTINUE TO SUPPORT LONG-TERM MARKET DEVELOPMENT

18 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)

  • 18.1 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)

19 SEPSIS DIAGNOSTICS MARKET, BY REGION

  • 19.1 INTRODUCTION
  • 19.2 NORTH AMERICA
    • 19.2.1 US
      • 19.2.1.1 High burden of sepsis and early adoption of advanced diagnostic technologies drive market leadership
    • 19.2.2 CANADA
      • 19.2.2.1 Strong public healthcare infrastructure and expanding adoption of advanced microbiology technologies support market growth
  • 19.3 EUROPE
    • 19.3.1 GERMANY
      • 19.3.1.1 Advanced clinical microbiology infrastructure and strong laboratory automation drive market leadership
    • 19.3.2 UK
      • 19.3.2.1 National sepsis initiatives and NHS investments continue to accelerate adoption of rapid diagnostics
    • 19.3.3 FRANCE
      • 19.3.3.1 Expansion of hospital microbiology networks and leadership of domestic diagnostic manufacturers drive growth
    • 19.3.4 ITALY
      • 19.3.4.1 Growing burden of HAIs supports adoption of advanced sepsis diagnostics
    • 19.3.5 SWITZERLAND
      • 19.3.5.1 Presence of global diagnostic manufacturers and strong healthcare investment support market growth
    • 19.3.6 SPAIN
      • 19.3.6.1 Increasing healthcare modernization and laboratory automation continue to strengthen market growth
    • 19.3.7 REST OF EUROPE
  • 19.4 ASIA PACIFIC
    • 19.4.1 CHINA
      • 19.4.1.1 Rapid healthcare modernization and expanding hospital laboratory infrastructure drive market growth
    • 19.4.2 JAPAN
      • 19.4.2.1 Advanced healthcare infrastructure and high adoption of innovative diagnostics support market expansion
    • 19.4.3 INDIA
      • 19.4.3.1 Expanding healthcare infrastructure and rising sepsis burden accelerate adoption of advanced diagnostics
    • 19.4.4 SOUTH KOREA
      • 19.4.4.1 Government investment in precision medicine and diagnostic innovation drives market expansion
    • 19.4.5 AUSTRALIA
      • 19.4.5.1 Strong clinical guidelines and high adoption of laboratory automation support market growth
    • 19.4.6 REST OF ASIA PACIFIC
  • 19.5 LATIN AMERICA
    • 19.5.1 BRAZIL
      • 19.5.1.1 Growing burden of infectious diseases and expansion of hospital laboratory infrastructure drive market growth
    • 19.5.2 MEXICO
      • 19.5.2.1 Healthcare modernization and expanding access to advanced diagnostics support market growth
    • 19.5.3 REST OF LATIN AMERICA
  • 19.6 MIDDLE EAST & AFRICA
    • 19.6.1 GCC COUNTRIES
      • 19.6.1.1 Healthcare modernization and government investments in advanced diagnostics drive regional growth
    • 19.6.2 REST OF MIDDLE EAST & AFRICA

20 COMPETITIVE LANDSCAPE

  • 20.1 INTRODUCTION
  • 20.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 20.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN SEPSIS DIAGNOSTICS MARKET
  • 20.3 REVENUE ANALYSIS, 2023-2025
  • 20.4 MARKET SHARE ANALYSIS, 2025
    • 20.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 20.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 20.5.1 STARS
    • 20.5.2 EMERGING LEADERS
    • 20.5.3 PERVASIVE PLAYERS
    • 20.5.4 PARTICIPANTS
    • 20.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 20.5.5.1 Company footprint
      • 20.5.5.2 Region footprint
      • 20.5.5.3 Product footprint
      • 20.5.5.4 Technology footprint
      • 20.5.5.5 Pathogen type footprint
      • 20.5.5.6 Test type footprint
      • 20.5.5.7 Method footprint
  • 20.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 20.6.1 PROGRESSIVE COMPANIES
    • 20.6.2 RESPONSIVE COMPANIES
    • 20.6.3 DYNAMIC COMPANIES
    • 20.6.4 STARTING BLOCKS
    • 20.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 20.6.5.1 Detailed list of key startups/SMEs
      • 20.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
      • 20.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
  • 20.7 COMPANY VALUATION & FINANCIAL METRICS
    • 20.7.1 FINANCIAL METRICS
    • 20.7.2 COMPANY VALUATION
  • 20.8 BRAND/PRODUCT COMPARISON
  • 20.9 COMPETITIVE SCENARIO
    • 20.9.1 PRODUCT LAUNCHES & APPROVALS
    • 20.9.2 DEALS
    • 20.9.3 OTHER DEVELOPMENTS

21 COMPANY PROFILES

  • 21.1 KEY PLAYERS
    • 21.1.1 BIOMERIEUX
      • 21.1.1.1 Business overview
      • 21.1.1.2 Products offered
      • 21.1.1.3 Recent developments
        • 21.1.1.3.1 Product launches & approvals
        • 21.1.1.3.2 Deals
        • 21.1.1.3.3 Other developments
      • 21.1.1.4 MnM view
        • 21.1.1.4.1 Key strengths
        • 21.1.1.4.2 Strategic choices
        • 21.1.1.4.3 Weaknesses & competitive threats
    • 21.1.2 BECTON, DICKINSON AND COMPANY (BD)
      • 21.1.2.1 Business overview
      • 21.1.2.2 Products offered
      • 21.1.2.3 Recent developments
        • 21.1.2.3.1 Product launches & approvals
        • 21.1.2.3.2 Deals
        • 21.1.2.3.3 Other developments
      • 21.1.2.4 MnM view
        • 21.1.2.4.1 Key strengths
        • 21.1.2.4.2 Strategic choices
        • 21.1.2.4.3 Weaknesses and competitive threats
    • 21.1.3 DANAHER
      • 21.1.3.1 Business overview
      • 21.1.3.2 Products offered
      • 21.1.3.3 Recent developments
        • 21.1.3.3.1 Deals
      • 21.1.3.4 MnM view
        • 21.1.3.4.1 Key strengths
        • 21.1.3.4.2 Strategic choices
        • 21.1.3.4.3 Weaknesses & competitive threats
    • 21.1.4 DIASORIN S.P.A.
      • 21.1.4.1 Business overview
      • 21.1.4.2 Products offered
      • 21.1.4.3 Recent developments
        • 21.1.4.3.1 Product launches & approvals
      • 21.1.4.4 MnM view
        • 21.1.4.4.1 Key strengths
        • 21.1.4.4.2 Strategic choices
        • 21.1.4.4.3 Weaknesses & competitive threats
    • 21.1.5 F. HOFFMANN-LA ROCHE LTD.
      • 21.1.5.1 Business overview
      • 21.1.5.2 Products offered
      • 21.1.5.3 Recent developments
        • 21.1.5.3.1 Product launches & approvals
      • 21.1.5.4 MnM view
        • 21.1.5.4.1 Key strengths
        • 21.1.5.4.2 Strategic choices
        • 21.1.5.4.3 Weaknesses & competitive threats
    • 21.1.6 THERMO FISHER SCIENTIFIC INC.
      • 21.1.6.1 Business overview
      • 21.1.6.2 Products offered
    • 21.1.7 BRUKER CORPORATION
      • 21.1.7.1 Business overview
      • 21.1.7.2 Products offered
      • 21.1.7.3 Recent developments
        • 21.1.7.3.1 Product launches & approvals
        • 21.1.7.3.2 Other developments
    • 21.1.8 ABBOTT
      • 21.1.8.1 Business overview
      • 21.1.8.2 Products offered
    • 21.1.9 SYSMEX CORPORATION
      • 21.1.9.1 Business overview
      • 21.1.9.2 Products offered
      • 21.1.9.3 Recent developments
        • 21.1.9.3.1 Deals
    • 21.1.10 SIEMENS HEALTHINEERS AG
      • 21.1.10.1 Business overview
      • 21.1.10.2 Products offered
    • 21.1.11 QIAGEN
      • 21.1.11.1 Business overview
      • 21.1.11.2 Products offered
      • 21.1.11.3 Recent developments
        • 21.1.11.3.1 Product launches & approvals
    • 21.1.12 SEEGENE INC.
      • 21.1.12.1 Business overview
      • 21.1.12.2 Products offered
      • 21.1.12.3 Recent developments
        • 21.1.12.3.1 Product launches & approvals
    • 21.1.13 PHC HOLDINGS CORPORATION
      • 21.1.13.1 Business overview
      • 21.1.13.2 Products offered
    • 21.1.14 QUIDELORTHO CORPORATION
      • 21.1.14.1 Business overview
      • 21.1.14.2 Products offered
    • 21.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
      • 21.1.15.1 Business overview
      • 21.1.15.2 Products offered
  • 21.2 OTHER PLAYERS
    • 21.2.1 EKF DIAGNOSTICS HOLDINGS PLC
    • 21.2.2 INFLAMMATIX, INC.
    • 21.2.3 BODITECH MED INC
    • 21.2.4 ALIFAX S.R.L.
    • 21.2.5 ADVANDX (OPGEN)
    • 21.2.6 FUJIREBIO
    • 21.2.7 IMMUNEXPRESS
    • 21.2.8 RESPONSE BIOMEDICAL CORPORATION
    • 21.2.9 DEEPULL DIAGNOSTICS S.L.
    • 21.2.10 SEKISUI DIAGNOSTICS

22 RESEARCH METHODOLOGY

  • 22.1 RESEARCH DATA
  • 22.2 SECONDARY DATA
    • 22.2.1 LIST OF SECONDARY SOURCES
    • 22.2.2 KEY DATA FROM SECONDARY SOURCES
    • 22.2.3 PRIMARY DATA
      • 22.2.3.1 List of primary sources
      • 22.2.3.2 Key data from primary sources
      • 22.2.3.3 Key industry insights
      • 22.2.3.4 Breakdown of primary interviews
  • 22.3 MARKET SIZE ESTIMATION
    • 22.3.1 TOTAL MARKET SIZE: SEPSIS DIAGNOSTICS MARKET
    • 22.3.2 BOTTOM-UP APPROACH
      • 22.3.2.1 Approach 1: Revenue estimation of key players
      • 22.3.2.2 Approach 2: Study of annual reports and investor presentations
      • 22.3.2.3 Approach 3: Primary interviews
      • 22.3.2.4 Growth forecast
      • 22.3.2.5 CAGR projections
    • 22.3.3 TOP-DOWN APPROACH
  • 22.4 DATA TRIANGULATION
  • 22.5 RESEARCH ASSUMPTIONS
    • 22.5.1 STUDY ASSUMPTIONS
    • 22.5.2 PARAMETRIC ASSUMPTIONS
    • 22.5.3 GROWTH RATE ASSUMPTIONS
  • 22.6 RESEARCH LIMITATIONS
  • 22.7 RISK ASSESSMENT

23 APPENDIX

  • 23.1 DISCUSSION GUIDE
  • 23.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 23.3 CUSTOMIZATION OPTIONS
  • 23.4 RELATED REPORTS
  • 23.5 AUTHOR DETAILS
Show more
Product Code: MD 4575

List of Tables

  • TABLE 1 SEPSIS DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 4 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 8 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 9 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 10 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 11 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 12 SEPSIS DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 14 KEY PATENTS IN SEPSIS DIAGNOSTICS MARKET, 2022-2026
  • TABLE 15 KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS MARKET
  • TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
  • TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • TABLE 25 KEY BUYING CRITERIA, BY PRODUCT
  • TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 27 SEPSIS DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 28 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 29 KEY BLOOD CULTURE MEDIA, BY COMPANY
  • TABLE 30 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 32 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 35 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 36 KEY ASSAYS & REAGENT KITS, BY COMPANY
  • TABLE 37 SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 41 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 KEY INSTRUMENTS/SYSTEMS, BY COMPANY
  • TABLE 44 SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 46 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 KEY SOFTWARE, BY COMPANY
  • TABLE 51 SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 58 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY REGION, 2024-2031 (USD MILLION)
  • TABLE 59 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 69 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 75 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 77 SEPSIS DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 99 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 100 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 102 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 105 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 108 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 111 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 112 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 114 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 120 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 125 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 126 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 127 NORTH AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 128 EUROPE: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 LATIN AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 MIDDLE EAST & AFRICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 133 NORTH AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 134 EUROPE: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 LATIN AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 MIDDLE EAST & AFRICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 138 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 139 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 140 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 143 LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 144 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 145 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 147 NORTH AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 EUROPE: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 LATIN AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 151 MIDDLE EAST & AFRICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 EUROPE: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 LATIN AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 MIDDLE EAST & AFRICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 FUNGAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 159 NORTH AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 EUROPE: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 162 LATIN AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 165 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 168 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 170 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 171 SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 172 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 175 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 178 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 181 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 183 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 185 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 186 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 191 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 192 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 196 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 197 SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 198 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 201 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 203 SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 204 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 205 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 207 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 208 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 210 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 211 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 212 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 214 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 215 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 216 SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 217 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 218 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 220 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 221 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 222 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 223 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 224 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 226 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 227 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 228 SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 229 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 230 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 232 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 233 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 234 SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 235 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 236 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 237 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 238 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 239 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 240 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 241 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 242 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 243 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 245 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 246 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 247 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 248 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 249 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 250 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 251 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 252 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 253 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 254 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 255 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 257 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 258 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 259 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, 2024-2031 (MILLION TESTS)
  • TABLE 260 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 261 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 262 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 263 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 264 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 265 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 267 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 268 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 271 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 272 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 273 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 274 US: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 275 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 276 US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 US: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 278 US: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 279 US: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 US: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 281 US: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 282 US: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 US: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 284 US: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 285 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 286 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 287 CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 288 CANADA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 289 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 290 CANADA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 291 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 292 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 293 CANADA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 294 CANADA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 295 CANADA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 296 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 297 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 298 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 299 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 300 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 301 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 302 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 303 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 306 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 307 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 308 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 309 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 310 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 311 GERMANY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 312 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 313 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 314 GERMANY: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 317 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 318 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 319 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 320 UK: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 321 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 322 UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 323 UK: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 324 UK: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 UK: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 UK: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 327 UK: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 328 UK: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 329 UK: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 330 UK: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 331 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 332 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 333 FRANCE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 335 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 336 FRANCE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 337 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 339 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 340 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 341 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 342 ITALY: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 343 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 344 ITALY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 345 ITALY: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 346 ITALY: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 ITALY: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 349 ITALY: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 350 ITALY: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 351 ITALY: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 352 ITALY: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 353 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 354 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 355 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 356 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 357 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 358 SWITZERLAND: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 359 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 361 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 362 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 363 SWITZERLAND: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 364 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 365 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 366 SPAIN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 367 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 368 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 369 SPAIN: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 370 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 371 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 372 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 373 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 374 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 375 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 376 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 377 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 378 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 379 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 380 REST OF EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 381 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 382 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 383 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 384 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 385 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 386 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 387 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 388 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 389 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 390 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 391 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 392 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 393 ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 394 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 395 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 396 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 397 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 398 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 399 CHINA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 400 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 401 CHINA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 402 CHINA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 403 CHINA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 404 CHINA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 405 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 406 CHINA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 407 CHINA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 408 CHINA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 409 CHINA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 410 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 411 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 412 JAPAN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 413 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 414 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 415 JAPAN: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 416 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 417 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 418 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 419 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 420 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 421 INDIA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 422 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 423 INDIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 424 INDIA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 425 INDIA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 426 INDIA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 427 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 428 INDIA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 429 INDIA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 430 INDIA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 431 INDIA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 432 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 433 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 434 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 435 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 436 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 437 SOUTH KOREA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 438 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 439 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 440 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 441 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 442 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 443 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 444 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 445 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 446 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 447 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 448 AUSTRALIA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 449 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 450 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 451 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 452 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 453 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 454 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 455 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 456 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 457 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 458 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 459 REST OF ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 460 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 461 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 462 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 463 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 464 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 465 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 466 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 467 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 468 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 469 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 470 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 471 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 472 LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 473 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 474 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 475 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 476 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 477 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 478 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 479 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 480 BRAZIL: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 481 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 482 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 483 BRAZIL: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 484 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 485 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 486 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 487 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 488 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 489 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 490 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 491 MEXICO: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 492 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 493 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 494 MEXICO: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 495 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 496 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 497 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 498 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 499 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 500 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 501 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 502 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 503 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 504 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 505 REST OF LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 506 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 507 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 508 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 509 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 510 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 511 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 512 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 513 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 514 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 515 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 516 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 517 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 518 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 519 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 520 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 521 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 522 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 523 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 524 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 525 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 526 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 527 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 528 GCC COUNTRIES: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 529 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 530 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 531 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 532 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 533 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 534 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 535 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 536 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 537 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
  • TABLE 538 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024-2031 (USD MILLION)
  • TABLE 539 REST OF MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 540 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024-2031 (USD MILLION)
  • TABLE 541 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024-2031 (USD MILLION)
  • TABLE 542 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 543 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024-2031 (USD MILLION)
  • TABLE 544 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 545 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN SEPSIS DIAGNOSTICS MARKET, JANUARY 2023-JUNE 2026
  • TABLE 546 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 547 SEPSIS DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 548 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 549 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 550 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT
  • TABLE 551 SEPSIS DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT
  • TABLE 552 SEPSIS DIAGNOSTICS MARKET: METHOD FOOTPRINT
  • TABLE 553 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 554 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 555 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 556 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 557 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 558 SEPSIS DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2023-JUNE 2026
  • TABLE 559 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 560 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 561 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 562 BIOMERIEUX: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 563 BIOMERIEUX: OTHER DEVELOPMENTS, JANUARY 2023-JUNE 2026
  • TABLE 564 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 565 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
  • TABLE 566 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 567 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2023-JUNE 2026
  • TABLE 568 BECTON, DICKINSON AND COMPANY (BD): OTHER DEVELOPMENTS, JANUARY 2023-JUNE 2026
  • TABLE 569 DANAHER: COMPANY OVERVIEW
  • TABLE 570 DANAHER: PRODUCTS OFFERED
  • TABLE 571 DANAHER: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 572 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 573 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 574 DIASORIN S.P.A: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 575 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 576 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 577 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 578 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 579 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 580 BRUKER CORPORATION: COMPANY OVERVIEW
  • TABLE 581 BRUKER CORPORATION: PRODUCTS OFFERED
  • TABLE 582 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 583 BRUKER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023-JUNE 2026
  • TABLE 584 ABBOTT: COMPANY OVERVIEW
  • TABLE 585 ABBOTT: PRODUCTS OFFERED
  • TABLE 586 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 587 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 588 SYSMEX CORPORATION: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 589 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 590 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 591 QIAGEN: COMPANY OVERVIEW
  • TABLE 592 QIAGEN: PRODUCTS OFFERED
  • TABLE 593 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 594 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 595 SEEGENE INC.: PRODUCTS OFFERED
  • TABLE 596 SEEGENE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 597 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 598 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 599 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 600 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 601 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 602 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
  • TABLE 603 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 604 INFLAMMATIX, INC.: COMPANY OVERVIEW
  • TABLE 605 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 606 ALIFAX S.R.L.: COMPANY OVERVIEW
  • TABLE 607 ADVANDX (OPGEN): COMPANY OVERVIEW
  • TABLE 608 FUJIREBIO: COMPANY OVERVIEW
  • TABLE 609 IMMUNEXPRESS: COMPANY OVERVIEW
  • TABLE 610 RESPONSE BIOMEDICAL CORPORATION: COMPANY OVERVIEW
  • TABLE 611 DEEPULL DIAGNOSTICS S.L.: COMPANY OVERVIEW
  • TABLE 612 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 613 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 SEPSIS DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL SEPSIS DIAGNOSTICS MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF SEPSIS DIAGNOSTICS MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN SEPSIS DIAGNOSTICS MARKET, 2025
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET
  • FIGURE 9 ASSAYS & REAGENT KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 BLOOD CULTURE (MICROBIOLOGY TESTING) SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 11 AUTOMATED DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 BACTERIAL SEPSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 WHOLE BLOOD SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 15 SINGLEPLEX SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 16 SEPSIS DIAGNOSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 17 HOSPITALS & SPECIALTY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20 SEPSIS DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 21 SEPSIS DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 22 SEPSIS DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 23 SEPSIS DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 24 SEPSIS DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 25 DEALS & FUNDING ACTIVITIES IN SEPSIS DIAGNOSTICS MARKET
  • FIGURE 26 PATENT ANALYSIS FOR SEPSIS DIAGNOSTICS MARKET, JANUARY 2016-DECEMBER 2025
  • FIGURE 27 MARKET POTENTIAL OF AI IN SEPSIS DIAGNOSTICS MARKET
  • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT
  • FIGURE 30 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 31 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET, 2023-2025 (USD MILLION)
  • FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 34 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 35 SEPSIS DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 36 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 37 EV/EBITDA OF KEY VENDORS
  • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 39 SEPSIS DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR SEPSIS DIAGNOSTICS
  • FIGURE 40 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 41 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025)
  • FIGURE 42 DANAHER: COMPANY SNAPSHOT (2025)
  • FIGURE 43 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 47 ABBOTT: COMPANY SNAPSHOT (2025)
  • FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 49 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025)
  • FIGURE 51 SEEGENE INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 52 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 55 RESEARCH DESIGN
  • FIGURE 56 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 57 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025-2030): IMPACT ON MARKET GROWTH AND CAGR
  • FIGURE 58 TOP-DOWN APPROACH
  • FIGURE 59 DATA TRIANGULATION
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!